Trials / Completed
CompletedNCT04564066
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Multiple Intravenous Infusions of Efgartigimod With Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | efgartigimod IV | intravenous infusions of efgartigimod |
| BIOLOGICAL | efgartigimod PH20 SC | subcutaneous injections of efgartigimod PH20 SC |
Timeline
- Start date
- 2020-08-18
- Primary completion
- 2020-12-24
- Completion
- 2021-02-11
- First posted
- 2020-09-25
- Last updated
- 2021-04-05
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04564066. Inclusion in this directory is not an endorsement.